Icotrokinra Ulcerative Colitis: Oral IL-23 Blocker & USMLE

A phase 2 trial published in the Oct. 15 issue of the New England Journal of Medicine reports that icotrokinra, a once-daily oral peptide that blocks the interleukin-23 (IL-23) receptor, produced a clinical response at week 12 significantly more often than placebo in adults with moderately to severely active ulcerative colitis. All three tested doses beat placebo. The data are early, and the report does not describe long-term efficacy or safety. Still, the study is a good prompt to review the IL-23/Th17 axis, which shows up repeatedly on USMLE Step 1 and Step 2 CK.

What happened

Maria T. Abreu, M.D., of Cedars Sinai in Los Angeles, and colleagues ran a phase 2, double-blind, randomized trial of oral icotrokinra in adults with moderately to severely active ulcerative colitis (UC). Participants were assigned to once-daily icotrokinra at 400 mg, 200 mg, or 100 mg, or to placebo. The groups had 63, 62, 64, and 63 participants, respectively.

The main finding concerned clinical response at week 12:

• 400 mg: 63%
• 200 mg: 58%
• 100 mg: 55%
• Placebo: 27%

All three doses were superior to placebo. For the 400-mg group, the researchers also reported higher rates than placebo for several other outcomes at week 12:

• Clinical remission: 30% vs 11%
• Symptomatic remission: 46% vs 19%
• Endoscopic improvement: 37% vs 14%

Through week 28, adverse events occurred in 60% (400 mg), 66% (200 mg), 66% (100 mg), and 62% (placebo) of participants. Serious adverse events occurred in 2%, 5%, 0%, and 10%, respectively.

Abreu said in a statement that "icotrokinra was effective even in hard-to-treat patients who had failed previous drug regimens," and that oral administration would widen the range of treatment options. The source material does not give numbers for that subgroup.

Why it matters

Advanced therapies for UC have mostly been injectable or infusion biologics, plus oral small molecules such as JAK inhibitors. Oral peptides are generally hard to develop because the GI tract tends to degrade them, so a peptide that works by mouth and hits a well-validated target is notable. If later trials hold up, the IL-23 pathway could be targeted without an injection. That is a hypothesis for now, not an established benefit.

For learners, the story also illustrates how a pathophysiologic idea becomes a drug class. IL-23 has been a target in inflammatory bowel disease (IBD) for years, and this trial tests a different way of blocking it: at the receptor rather than at the cytokine.

What to know for the USMLE — high-yield review of IL-23 and IBD

• IL-23 structure: IL-23 is a heterodimer of p19 and p40. The p40 subunit is shared with IL-12. The IL-23 receptor pairs IL-23R with IL-12Rβ1. Receptor signaling runs through JAK2/TYK2 and STAT3.
• Th17 axis: IL-23 helps maintain and expand Th17 cells, which produce IL-17 and IL-22. Dendritic cells and macrophages are the main sources of IL-23. IL-23/Th17 signaling drives mucosal inflammation in IBD and also contributes to psoriasis and spondyloarthropathies. Compare this with IL-12, which drives Th1 differentiation (via STAT4) and IFN-γ production.
• Drug targets in IBD:
• Anti-TNF (infliximab, adalimumab)
• Vedolizumab (anti-α4β7 integrin, gut-selective)
• Ustekinumab (anti-p40, so it blocks both IL-12 and IL-23)
• Anti-p19 antibodies (risankizumab, mirikizumab, guselkumab), which block IL-23 only
• JAK inhibitors (tofacitinib, upadacitinib)

Icotrokinra differs from the p19 antibodies in two ways: it is a peptide taken orally, and it blocks the receptor instead of the cytokine. This trial did not compare icotrokinra with any of these drugs, so avoid cross-trial comparisons.

• UC vs Crohn disease:
• UC: continuous disease starting at the rectum; limited to mucosa and submucosa; crypt abscesses, pseudopolyps; bloody diarrhea; lead-pipe colon on imaging; association with p-ANCA and primary sclerosing cholangitis; risk of toxic megacolon and colorectal cancer; colectomy is curative for the bowel disease.
• Crohn disease: skip lesions; transmural inflammation; noncaseating granulomas; "cobblestone" mucosa, creeping fat; strictures and fistulas; string sign; can involve any part of the GI tract; ASCA association.
• Standard UC approach (conceptual): 5-ASA agents (mesalamine) for mild-to-moderate disease, corticosteroids for flares, and biologics or small molecules for moderate-to-severe or refractory disease. Know the indications for surgery: massive bleeding, perforation, toxic megacolon, dysplasia or cancer, and refractory disease.
• Trial vocabulary: Phase 2 trials explore efficacy signals and dose-response. They are not designed to establish definitive efficacy or rare safety events. Questions may ask you to tell a phase 2 dose-ranging study from a phase 3 confirmatory trial.
• Safety reasoning: When a drug modulates immune pathways, expect questions on infection risk and screening. Screening for latent TB is classic with anti-TNF therapy. The icotrokinra report here gives only overall adverse event rates, with no breakdown by type.

Limitations

• Phase 2 and modest size. The four groups totaled about 250 participants, so estimates are imprecise and rare adverse events could not be detected.
• Short efficacy window. The primary outcome was measured at week 12. The source material does not report longer-term efficacy, and safety data run through week 28.
• Safety is only partly described. Overall adverse event rates were similar across groups (60–66%). Serious adverse events were 2%, 5%, 0%, and 10%. These numbers are small and not sufficient to draw conclusions about safety, and the source does not specify the types of events.
• Subgroup claims lack numbers. The investigator's comment about patients who had failed prior therapies is encouraging, but no data for that subgroup appear in the source material.
• No head-to-head comparison. The trial compared icotrokinra with placebo only, so its standing relative to existing biologics or JAK inhibitors is unknown.
• Definitions not detailed. The source does not spell out how clinical response, clinical remission, and symptomatic remission were defined, so check the full paper before quoting thresholds.
• Dose pattern. The 400-mg group is the one with additional outcomes reported. The source does not say whether the other doses showed the same pattern for those outcomes.

FAQ

What is icotrokinra?

It is a peptide that blocks the interleukin-23 receptor and is taken by mouth once daily. In the reported phase 2 trial it was tested in adults with moderately to severely active ulcerative colitis.

How is icotrokinra different from anti-IL-23 p19 antibodies?

Anti-p19 antibodies bind the IL-23 cytokine itself and are given by injection or infusion. Icotrokinra, according to the source, targets the IL-23 receptor and is given orally. Both approaches interrupt the IL-23/Th17 pathway, but this trial did not compare them.

Is icotrokinra approved for ulcerative colitis?

The source material does not say anything about approval. It describes a phase 2 trial, and it does not report larger confirmatory trials or long-term outcomes.

Key takeaways

• In a phase 2 NEJM trial, once-daily oral icotrokinra beat placebo for week-12 clinical response in moderately to severely active UC (55–63% across doses vs 27%), with higher remission and endoscopic improvement rates at 400 mg.
• For USMLE, tie this to the IL-23 (p19/p40) → Th17 → IL-17/IL-22 axis, the difference between anti-p40 and anti-p19 agents, and the classic features separating UC from Crohn disease.
• The results are early: phase 2, short follow-up, no head-to-head comparisons, and limited safety data. Longer and larger studies are needed.